È cambiata la prognosi della fibrosi cistica? - Primula Multimedia

24
Raia
32. Balfour LI, Klein N, Dinwiddie R. Randomized
controlled trial of inhaled corticosteroids (fluticasone
propionate) in cystic fibrosis. Arch Dis Child 1997;
77: 124-130.
33. Konstan MW, Byard RJ, Hoppel CL, Davis PB.
Effect of high-dose ibuprofen in patients with cystic
fibrosis. N Engl J Med 1995; 332: 848-854.
34. Jaffe A, Bush A. Macrolides in cystic fibrosis. In:
Rubin BK, Tamaoki J (eds). “Antibiotics as antiinflammatory
and immunomodulatory agents”.
Basel: Birkhauser Verlag 2004.
35. Saiman I. The use of azithromycin in patients
with cystic fibrosis. Curr Opin Pulm Med 2004; 10:
515-523.
36. Amsden GW. Anti-inflammatory effects of
macrolides- an underappreciated benefit in the
treatment of community-acquired respiratory tract
infections and chronic inflammatory pulmonary conditions?
J Antimicrob Chemother 2005; 55: 10-21.
37. Gotfried MH. Macrolides for the treatment of
chronic sinusitis, asthma and COPD. Chest 2004;
125: 52S-61S.
38. Parnham MJ. Immunomodulatory effects of
antimicrobials in the therapy of respiratory tract
infections. Curr Opin Infect Dis 2005; 18: 125-131.
39. Wagner T, Soong G, Sokol S, et al. Effects of
azithromycin on clinical isolates of Pseudomonas
aeruginosa from cystic fibrosis patients. Chest 2005;
128: 912-919.
40. Mall M, Grubb BR, Harkema JR, et al.
Increased airway epithelial Na(+) absorption produces
cystic fibrosis-like lung disease in mice. Nat
Med 2004; 10: 487-493.
41. Raia V, Maiuri L, Ciacci C, et al. Inhibition of
p38 mitogen activated protein kinase controls airway
inflammation in cystic fibrosis. Thorax 2005;
60: 773-780.
42. Maiuri L, Ciacci C, Ricciardelli I, et al.
Association between innate response to gliadin and
activation of pathogenic T cells in coeliac disease.
Lancet 2003; 362: 30-37.
43. Kingdom TT, Lee KC, FitzSimmons SC, et al.
Clinical characteristics and genotype analysis of
patients with cystic fibrosis and nasal polyposis
requiring surgery. Arch Otolaryngol Head Neck
Surg 1996; 122: 1209-1213.
44. Kim JY, Kang YS, Lee JW, et al. p38 is essential
for the assembly and stability of macromolecular
tRNA synthetase complex: implications for its physiological
significance. Proc Natl Acad Sci USA 2002;
99: 7912-7916.
45. Kumar S, Boehm J, Lee JC. p38 MAP kinases:
key signalling molecules as therapeutic targets for
inflammatory diseases. Nat Rev Drug Discov
2003; 2: 717-726.
46. Schultz RM. Potential of p38 MAP kinase
inhibitors in the treatment of cancer. Prog Drug Res
2003; 60: 59-92.
47. Lee JC, Kumar S, Griswold DE, et al. Inhibition
of p38 MAP kinase as a therapeutic strategy.
Immunopharmacology 2000; 47: 185-201.
48. Stelmach JE, Liu L, Patel SB, et al. Design and
synthesis of potent, orally bioavailable dihydroquinazolinone
inhibitors of p38 MAP kinase. Bioorg Med
Chem Lett 2003; 13: 277-280.
49. Newton R, Holden N. Inhibitors of p38 mitogen-activated
protein kinase: potential as antiinflammatory
agents in asthma? BioDrugs 2003;
17: 113-129.
BIBLIOGRAFIA